EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis

Júlia Opolski Nunes da Silva, Rodrigo Ribeiro E Silva, Paulo Victor Zattar Ribeiro, Patrícia Silva Farah, Raquel Bissacotti Steglich

Anais Brasileiros de Dermatologia · 2025

DOI: 10.1016/j.abd.2024.08.008 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Anais Brasileiros de Dermatologia, 2025. Verfasst von Júlia Opolski Nunes da Silva und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Universidade de São Paulo, Ribeirão Preto, SP, Brazil. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Evaluate the safety and efficacy of dupilumab in treating moderate-to-severe bullous pemphigoid.

Methods

The authors performed a systematic review and meta-analysis of comparative studies of Dupilumab combined with corticosteroids and conventional corticosteroid therapy alone in patients with moderate-to-severe bullous pemphigoid. PubMed, Embase and Cochrane databases were searched for studies published up to December 2023. Data were extracted from published reports and quality assessment was performed according to Cochrane recommendations.

Results

A total of four studies involving 127 patients were included, of which 53 received Dupilumab combined with corticosteroids, while the other 74 were administered corticosteroids alone. Regarding efficacy, Dupilumab the time before new blister formation stopped (MD = -5.13 days; 95% CI -7.12 to -3.15; p < 0.0001) and demonstrated a greater reduction in Bullous Pemphigoid Disease Area Index (MD = -3.90; 95% CI -5.52 to -2.27; p < 0.0001) and Numeric Rating Scale for Pruritus (SMD = -1.37; 95% CI -2.02 to -0.72; p < 0.0001) compared with patients who received conventional therapy. However safety endpoints, adverse events (RR = 0.78; 95% CI 0.58 to 1.05; p = 0.10) and relapses (RR = 0.50; 95% CI 0.19 to 1.36; p = 0.17) showed no significance. The main limitations were retrospective studies with small samples and limited results in clinical practice and a moderate overall risk of bias.

Conclusion

Compared with conventional therapy, Dupilumab decreased the time before new blister formation stopped in 5.13 days, as well as Disease Area Index and Pruritus, without interfering with adverse events and relapse.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansTreatment OutcomeSeverity of Illness IndexAdrenal Cortex HormonesDrug Therapy, Combination

Stichwörter der Autor:innen

DupilumabInterleukin-4MethylprednisolonePemphigoid, bullousPruritus

Substanzen

Antibodies, Monoclonal, HumanizeddupilumabAdrenal Cortex HormonesDermatologic Agents

Autor:innen und Institutionen

  • Department of Medicine, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
  • Department of Medicine, Universidade de São Paulo, Ribeirão Preto, SP, Brazil. Electronic address: pvzattar@hcrp.usp.br.
  • Department of Dermatology, Universidade Federal de Santa Catarina, Florianópolis, SP, Brazil.
  • Department of Dermatology, Universidade da Região de Joinville, Joinville, SC, Brazil.

Zitieren

APA

da Silva, J. O. N., E Silva, R. R., Zattar Ribeiro, P. V., Farah, P. S., & Steglich, R. B. (2025). Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2024.08.008

Vancouver

da Silva JON, E Silva RR, Zattar Ribeiro PV, Farah PS, Steglich RB. Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis. Anais Brasileiros de Dermatologia. 2025. doi:10.1016/j.abd.2024.08.008

BibTeX
@article{daSilva2025,
  author = {da Silva, Júlia Opolski Nunes and E Silva, Rodrigo Ribeiro and Zattar Ribeiro, Paulo Victor and Farah, Patrícia Silva and Steglich, Raquel Bissacotti},
  title = {Efficacy and safety of dupilumab in patients with moderate-to-severe bullous pemphigoid: a systematic review and meta-analysis},
  journal = {Anais Brasileiros de Dermatologia},
  year = {2025},
  doi = {10.1016/j.abd.2024.08.008}
}
Kostenlos starten →